Annual report pursuant to Section 13 and 15(d)

Segment Reporting (Tables)

v3.19.3
Segment Reporting (Tables)
12 Months Ended
Dec. 31, 2018
Segment Reporting [Abstract]  
Schedule of Segment Information

Selected financial information for the Company’s operating segments is as follows:

 

      Year Ended December 31,  
      2018       2017  
Net revenues - External                
Clinical Laboratory Operations   $ 131,014     $ 2,210,318  
Hospital Operations     14,417,676       877,898  
    $ 14,548,690     $ 3,088,216  
Loss from operations                
Clinical Laboratory Operations   $ (2,247,499 )   $ (4,672,768 )
Hospital Operations     (6,434,538 )     (4,800,539 )
Corporate     (4,542,583 )     (6,602,800 )
    $ (13,224,620 )   $ (16,076,107 )
Depreciation and amortization                
Clinical Laboratory Operations   $ 764,445     $ 1,639,954  
Hospital Operations     498,352       73,985  
Corporate     1,047       1,382  
    $ 1,263,844     $ 1,715,321  
Capital expenditures                
Clinical Laboratory Operations   $ -     $ -  
Hospital Operations     213,105       1,422,002  
    $ 213,105     $ 1,422,002  

 

    Year Ended December 31,  
    2018     2017  
Total assets                
Clinical Laboratory Operations   $ 271,426     $ 1,503,520  
Hospital Operations     13,568,933       2,549,504  
Corporate     2,707,416       3,436,773  
Assets of AMSG and HTS classified as held for sale     152,171       255,566  
Eliminations     (2,500,646 )     (1,454,570 )
    $ 14,199,300     $ 6,290,794